EU says MS drug Gilenya needs heart monitoring

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

EU says MS drug Gilenya needs heart monitoring

Postby MSUK » Mon Jan 23, 2012 1:26 am

Image

The European Medicines Agency advised doctors to continuously monitor patients for six hours after giving them a first dose of Novartis AG's multiple sclerosis drug Gilenya, casting a shadow over the potential blockbuster product.

The move came as the organisation started a review into the safety of the medicine, following reports of heart problems in patients and the death of one person in the United States within 24 hours of starting treatment.

The Swiss drugmaker said last month it was investigating whether Gilenya, seen by analysts as a potential multibillion-dollar seller, caused the death of the 59-year-old U.S. patient....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2092
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: EU says MS drug Gilenya needs heart monitoring

Postby arabia » Sat Feb 25, 2012 11:59 am

thanks for sharing.
User avatar
arabia
Newbie
 
Posts: 8
Joined: Sun Mar 13, 2011 4:00 pm


Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users